Pneumonia vaccine – USA

Pneumonia vaccine – USA

Decision on IPR: Mar 13, 2019

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Final Written Decision
IPR2017-02131
09/19/2017
03/22/2018
Merck
9,492,559
Pfizer Inc.
claims 1–10, 16–19, & 38–45 are  unpatentable
IPR2017-02132
09/19/2017
03/22/2018
Merck
9,492,559
Pfizer Inc.
claims 1–10, 16–19, and 38–45 are unpatentable
IPR2017-02136
09/19/2017
03/22/2018
Merck
9,492,559
Pfizer Inc.
claims 11–15 and 20–37 are unpatentable
IPR2017-02138
09/19/2017
03/22/2018
Merck
9,492,559
Pfizer Inc.
claims 11–15 and 20–37 are unpatentable
Previously Merck also filed other IPRs (IPR2018-00187 & IPR2018-00188) on 11/20/2017 of which IPR’187 was instituted & IPR’188 was denied by PTAB.

US 9,492,559 (Pfizer Inc.; Exp: Jan 15, 2035) :

1. An immunogenic composition comprising a Streptococcus pneumoniae serotype 22F glycoconjugate, wherein the glycoconjugate has a molecular weight of between 1000 kDa and 12,500 kDa and comprises an isolated capsular polysaccharide from S. pneumoniae serotype 22F and a carrier protein, and wherein a ratio (w/w) of the polysaccharide to the carrier protein is between 0.4 and 2.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved